About
Team
Science
Join Us
News
Back
Team
Back
News

Press Releases

September 9, 2024 Upstream Bio Announces Oral Presentation of New Data from a Phase 1b Multiple Ascending Dose Trial of Verekitug (UPB-101) in Adults with Asthma at the European Respiratory Society Congress
May 22, 2024 Upstream Bio Presents Results from a Dose Ranging Study of Verekitug (UPB-101) in Adults with Asthma at the American Thoracic Society International Conference
May 15, 2024 Upstream Bio to Present Results from a Dose Ranging Study of Verekitug (UPB-101) in Adults with Asthma at the American Thoracic Society (ATS) International Conference
April 2, 2024 Upstream Bio Announces Appointment of Rand Sutherland as CEO and Additions to Leadership Team
March 7, 2024 Upstream Bio Initiates a Phase 2 Clinical Trial of Verekitug (UPB-101) in Severe Asthma and Doses First Patients
January 3, 2024 Upstream Bio Announces Dosing of First Patients in a Phase 2 Clinical Trial of Verekitug (UPB-101) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
October 24, 2023 Upstream Bio Announces Positive Phase 1b Interim Data in Asthma and Company Progress Toward Phase 2
June 8, 2023 Upstream Bio Announces $200M Series B Financing to Advance UPB-101 for Allergic and Inflammatory Diseases
May 22, 2023 Upstream Bio Presents New Phase 1 Clinical Data on UPB-101 at the American Thoracic Society (ATS) International Conference
May 12, 2023 Upstream Bio to Present New Clinical Data from Phase 1 Study of UPB-101 at the American Thoracic Society (ATS) International Conference
February 7, 2023 Upstream Bio Announces the Appointment of Marcella Ruddy, M.D., to the Board of Directors
October 10, 2022 Upstream Bio Announces Clinical Advisory and Leadership Appointments
August 9, 2022 Upstream Bio Announces Dosing of First Patient in a Phase 1b Clinical Trial of UPB-101 in Asthma
June 2, 2022 Upstream Bio Launches with $200M Series A Financing to Advance Novel Therapeutics for Allergic and Inflammatory Diseases